Effectiveness and Safety of Rosuvastatin in Reducing LDL Cholesterol Levels: An Observational Study.

Background: Dyslipidemia, characterized by elevated levels of low-density lipoprotein (LDL) cholesterol, is a significant risk factor for cardiovascular diseases. Rosuvastatin, a statin medication, is commonly prescribed to lower LDL cholesterol levels. However, comprehensive observational studies assessing its effectiveness and safety in real-world settings are limited. This observational study aimed to evaluate the effectiveness and safety of rosuvastatin in reducing LDL cholesterol levels among individuals with dyslipidemia. Methods: A sample of 100 participants with dyslipidemia, aged 45-65 years, was enrolled in a 12-week observational study. Baseline characteristics, including age, gender distribution, and baseline LDL cholesterol levels, were recorded. Participants received rosuvastatin therapy as per standard clinical practice. The primary outcome measure was the change in LDL cholesterol levels from baseline to the end of the 12-week treatment period. Safety assessments included monitoring for adverse events, liver function tests, and creatine kinase levels. Compliance and adherence to medication were also evaluated. Results: Following 12 weeks of rosuvastatin therapy, a significant reduction in LDL cholesterol levels was observed across the sample (mean reduction: 30 mg/dL ± 5 mg/dL). Subgroup analysis based on baseline LDL cholesterol levels demonstrated consistent reductions, with greater reductions observed in participants with higher baseline LDL cholesterol levels. Rosuvastatin therapy was well-tolerated, with no serious adverse events reported. Common adverse effects were mild and transient, including muscle aches, gastrointestinal discomfort, and headache. Compliance with therapy was high, with 95% of participants completing the treatment period and adherence rates exceeding 90%. Secondary outcomes indicated improvements in total cholesterol (mean reduction: 35 mg/dL ± 6 mg/dL), triglycerides (mean reduction: 25 mg/dL ± 4 mg/dL), and HDL cholesterol (mean increase: 5 mg/dL ± 2 mg/dL). Conclusion: This observational study provides evidence supporting the effectiveness and safety of rosuvastatin in reducing LDL cholesterol levels among individuals with dyslipidemia. Rosuvastatin therapy was well-tolerated and associated with improvements in lipid profiles. These findings highlight the potential of rosuvastatin as a therapeutic option for managing dyslipidemia and reducing cardiovascular risk. [ABSTRACT FROM AUTHOR]